Saturday 15 November 2014

Workshop - Paul G. Swingle, Ph.D.

Basics of the ClinicalQ Database and Braindriving
Paul G. Swingle, Ph.D.
1-day Workshop

Neurotherapy is rapidly evolving into a primary care option for many disorders. Problems with mood, anxiety, sleep quality, learning, cognitive processing, pain, addictions, anger management, and age related memory are all amenable to rapid assessment and treatment. The assessment procedures are simple and straight forward involving assessment of a limited number of brain sites. Treatment options other than neurofeedback have been developed to markedly accelerate neurotherapy. These complementary techniques markedly facilitate neurotherapy as a viable primary care alternative to dangerous and often ineffective pharmaceuticals.

The workshop starts with the precise ClinicalQ assessment procedure that determines treatment strategies. Emphasis is on Braindriving treatment procedures including review of major unconditioned stimuli required for treatment. Other treatment options including neurofeedback, AVS, CES, energy psychology methods, craniosacral manipulations, harmonic sounds, electrostimulation, and behavior therapies appropriate for a wide range of disorders are presented. Practitioners will be able to immediately apply these efficient techniques. Conditions that require full QEEG and normative data base procedures will be identified as will conditions in which the more aggressive treatments are contraindicated.

Neurotherapeutic Treatment of Depression
Paul D. Swingle, Ph.D.
1-day Workshop

Neurotherapy has been shown to be very efficient for treatment of the many forms of “depression.” Most important, EEG assessments based on clinical normed data bases precisely identifies the various forms of this condition and critically identifies those conditions that are mistakenly treated as depression. Severe anxiety, for example, has a very different neurological profile from depression but clients often report “depression” because their lives are in shambles as a result of disabling anxiety.

Many clinical clients also have histories of emotional trauma and many also present for treatment as a result of on-going or recent traumatic stress. The ClinicalQ assessment helps identify those conditions that may be more efficaciously treated with therapies other than those neurologically based.

The ClinicalQ EEG intake assessment is remarkably accurate for identifying clients with unresolved post-traumatic stress, endogenous predispositions to depression or anxiety as well as other conditions that mimic “depression.” Combining the EEG markers for “trauma” with endogenous neurological conditions that affect manifestation of depression provide guides for neurotherapeutic treatment.

The workshop reviews the diagnostic procedures for identifying the neurological conditions associated with the client’s symptoms as well as identifying the neurological “foot-print” for exposure to severe emotional stressors that have not been resolved.

Neurotherapy is not a stand-alone treatment modality. The second portion of the workshop, therefore, focuses on the combination of neurotherapy, particularly braindriving technology, with other therapeutic procedures for very effective treatment of the wide array of clinical conditions that are the basis for clients seeking treatment for “depression.”

About Dr. Paul G. Swingle

Dr. Swingle is a Fellow of the Canadian Psychological Association and a former Lecturer in Psychiatry at Harvard Medical School. Professor Swingle formerly held the posts of Chairman of the Faculty of Child Psychology and Clinical Supervisor at the University of Ottawa. He has taught at McGill University, Dalhousie University and McMaster University. He is a Registered Psychologist in British Columbia and is (BCIA) Certified in Biofeedback and Neurotherapy. Since 1997 he has been in private practice in Vancouver, British Columbia. His most recent book Biofeedback for the Brain (2008) was published by Rutgers University Press.

About the ClinicalQ nd BrainDryvr Software Suite